Unlock stock picks and a broker-level newsfeed that powers Wall Street.
NYSE - Nasdaq Real Time Price USD

Bausch + Lomb Corporation (BLCO)

Compare
14.37
-0.13
(-0.90%)
As of 1:47:04 PM EDT. Market Open.
Loading Chart for BLCO
  • Previous Close 14.50
  • Open 14.43
  • Bid 14.21 x 1100
  • Ask 14.24 x 1100
  • Day's Range 14.23 - 14.56
  • 52 Week Range 13.16 - 21.69
  • Volume 456,094
  • Avg. Volume 672,906
  • Market Cap (intraday) 5.094B
  • Beta (5Y Monthly) 0.49
  • PE Ratio (TTM) --
  • EPS (TTM) -0.90
  • Earnings Date Apr 30, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 18.86

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lenses that are indicated for therapeutic use and provides optical correction during healing. It also offers contact lens care products, eye vitamins, mineral supplements, and over-the-counter eye drops that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief. The Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery. The company sells its products and services through direct sales forces and independent distributors. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation operates as a subsidiary of Bausch Health Companies Inc.

www.bausch.com

13,500

Full Time Employees

December 31

Fiscal Year Ends

Recent News: BLCO

View More

Performance Overview: BLCO

Trailing total returns as of 4/1/2025, which may include dividends or other distributions. Benchmark is S&P/TSX Composite index (^GSPTSE) .

YTD Return

BLCO
19.22%
S&P/TSX Composite index (^GSPTSE)
1.40%

1-Year Return

BLCO
15.77%
S&P/TSX Composite index (^GSPTSE)
12.53%

3-Year Return

BLCO
22.32%
S&P/TSX Composite index (^GSPTSE)
13.73%

5-Year Return

BLCO
22.32%
S&P/TSX Composite index (^GSPTSE)
93.89%

Compare To: BLCO

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: BLCO

View More

Valuation Measures

Annual
As of 3/31/2025
  • Market Cap

    5.14B

  • Enterprise Value

    9.62B

  • Trailing P/E

    --

  • Forward P/E

    15.41

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    1.06

  • Price/Book (mrq)

    0.79

  • Enterprise Value/Revenue

    2.01

  • Enterprise Value/EBITDA

    16.01

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -6.62%

  • Return on Assets (ttm)

    0.96%

  • Return on Equity (ttm)

    -4.53%

  • Revenue (ttm)

    4.79B

  • Net Income Avi to Common (ttm)

    -317M

  • Diluted EPS (ttm)

    -0.90

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    305M

  • Total Debt/Equity (mrq)

    75.43%

  • Levered Free Cash Flow (ttm)

    188.38M

Research Analysis: BLCO

View More

Company Insights: BLCO

Research Reports: BLCO

View More

People Also Watch